Literature DB >> 15786703

Current challenges in human embryonic stem cell research: directed differentiation and transplantation tolerance.

P Ponsaerts1, V F I van Tendeloo, P G Jorens, Z N Berneman, D R van Bockstaele.   

Abstract

Research towards potential curative transplantation of human embryonic stem (hES) cell-derived grafts in a variety of diseases has become an important topic since the successful derivation and propagation of hES cells from the inner cell mass of a blastocyst. However, clinical applicability can only be established after intensive laboratory studies that should elaborate on two major topics: A) the development of efficient, controlled and stable hES cell differentiation protocols for any specific cell type, and B) the induction of immunological tolerance against transplanted allogeneic hES cell-derived cell types. This review will briefly discuss: A) current possibilities in hES cell differentiation, followed by the development of viral, DNA and mRNA-based gene transfer strategies for hES cells, and B) possible immune modulation strategies for inducing immune tolerance against allogeneic hES cell transplants.

Entities:  

Mesh:

Year:  2004        PMID: 15786703

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  3 in total

1.  Derivation of human embryonic stem cell lines from single blastomeres of low-quality embryos by direct plating.

Authors:  Gang Yang; Qingyun Mai; Tao Li; Canquan Zhou
Journal:  J Assist Reprod Genet       Date:  2013-07-09       Impact factor: 3.412

2.  Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.

Authors:  Yuhua Wang; Hsing-Hao Su; Yang Yang; Yunxia Hu; Lu Zhang; Pilar Blancafort; Leaf Huang
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

Review 3.  Therapeutic potentials of human embryonic stem cells in Parkinson's disease.

Authors:  Mary B Newman; Roy A E Bakay
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.